Increasing evidence suggests that histone posttranslational modifications (PTMs) function in a combinatorial fashion to regulate the diverse activities associated with chromatin. Yet how these patterns of histone PTMs influence the adapter proteins known to bind them is poorly understood. In addition, how histone-specific antibodies are influenced by these same patterns of PTMs is largely unknown. Here we examine the binding properties of histone-specific antibodies and histone-interacting proteins using peptide arrays containing a library of combinatorially modified histone peptides. We find that modification-specific antibodies are more promiscuous in their PTM recognition than expected and are highly influenced by neighboring PTMs. Furthermore, we find that the binding of histone-interaction domains from BPTF, CHD1, and RAG2 to H3 lysine 4 trimethylation is also influenced by combinatorial PTMs. These results provide further support for the histone code hypothesis and raise specific concerns with the quality of the currently available modification-specific histone antibodies.
Increasing evidence suggests that histone posttranslational modifications (PTMs) function in a combinatorial fashion to regulate the diverse activities associated with chromatin. Yet how these patterns of histone PTMs influence the adapter proteins known to bind them is poorly understood. In addition, how histone-specific antibodies are influenced by these same patterns of PTMs is largely unknown. Here we examine the binding properties of histone-specific antibodies and histone-interacting proteins using peptide arrays containing a library of combinatorially modified histone peptides. We find that modification-specific antibodies are more promiscuous in their PTM recognition than expected and are highly influenced by neighboring PTMs. Furthermore, we find that the binding of histone-interaction domains from BPTF, CHD1, and RAG2 to H3 lysine 4 trimethylation is also influenced by combinatorial PTMs. These results provide further support for the histone code hypothesis and raise specific concerns with the quality of the currently available modification-specific histone antibodies.
Results and Discussion
Protein posttranslational modifications (PTMs), such as phosphorylation, methylation, acetylation, and ubiquitination, regulate many processes, such as protein degradation, protein trafficking, and mediation of protein-protein interactions [1] . Perhaps the best-studied PTMs are those found to be associated with histone proteins. More than 100 histone PTMs have been described, and they largely function by recruiting protein factors to chromatin, which in turn drives processes such as transcription, replication, and DNA repair [2] . Likewise, dozens of chromatin-associating factors have been identified that bind to distinct histone PTMs, and hundreds of modificationspecific histone antibodies have been developed to understand the in vivo function of these modifications [3, 4] .
The enormous number of potential combinations of histone PTMs represents a major obstacle to our understanding of how PTMs regulate chromatin-templated processes, as well as to our ability to develop high-quality diagnostic tools for chromatin and epigenetic studies. The same obstacle applies to other proteins regulated by combinatorial PTMs: for example, p53, RNA polymerase, and nuclear receptors [5] [6] [7] . To that end, we developed a peptide array-based platform to begin to address how both histone-interacting proteins and antibodies recognize combinations of PTMs. We focused primarily on the recognition of PTMs associated with the N-terminal tail of histone H3, but this approach is useful for the study of other histone modifications and combinatorial PTMs found on other nonhistone proteins.
We generated a library of 110 synthetic histone peptides bearing either single or combinatorial PTMs and a biotin moiety for immobilization (Figure 1 ; see also Table S1 available online). Prior to printing, all peptides were subjected to rigorous quality control to verify their accuracy. This is significant because extensive peptide purification and mass spectrometric analysis is not possible with other recently described array technologies used to study combinatorial histone PTMs [8] . Another significant advancement in our method was the introduction of a biotinylated fluorescent tracer molecule, which served as a positive control for the quality of our printing in all experiments. Lastly, peptides were printed as a series of six spots, two times per slide by two different pins, yielding 24 independent measurements of every binding interaction per slide. These measures were adopted to minimize binding artifacts due to pin variation or inconsistencies on the slide surface. Thus, these arrays offer a large number of extensively characterized histone peptide substrates suitable for the assessment of effector protein or antibody binding.
We initially used our arrays to ask two fundamental questions regarding the recognition of histone PTMs: (1) How well do modification-directed antibodies recognize their intended epitope? and (2) What impact, if any, do combinatorial PTMs have on antibody recognition? We tested more than 20 commercially available antibodies raised against individual modifications on histone tails (see Tables S2 and S3 for information regarding antibodies and experimental conditions) . Generally, we found that antibodies were reasonably proficient at recognizing their target modification ( Figure S1 ). However, we found several exceptions, notably the discrimination between different methyllysine states by methyl-specific antibodies and the recognition of histone H3 lysine 14 acetylation (H3K14ac).
To explore methyllysine recognition, we tested the specificity of commercial antibodies raised against the three different methylated forms (mono-, di-, and trimethyl) of H3 at lysines 4 and 79 (H3K4me and H3K79me) (Figure 2 ). These antibodies were generally specific for their target lysine residue; however, both the trimethyl-and dimethyl-directed antibodies showed measurable cross-reactivity with dimethyllysine and monomethyllysine, respectively ( Figure 2A and Figure S2 ). This finding has particular biological importance, because each methylation state of a given histone lysine residue is thought to mediate different biological outcomes through the recruitment of distinct chromatin-associated factors [9] . For example, H3K4me3 is well correlated with transcriptional activation through the recruitment of histone acetyltransferases and the preinitiation complex of transcription [10] [11] [12] . Conversely, H3K4me2 was reported to recruit the Set3 histone deacetylase complex [9] . The ability to distinguish between these methyl states is therefore necessary to dissect how H3K4 methylation controls the balance of histone acetylation and/or deacetylation at transcribed genes.
We also tested a number of antibodies raised against acetyllysine found at position 14 of histone H3 (H3K14ac). Unlike lysine methylation, our arrays detected that several of these antibodies had difficulty in recognizing their target sequence, preferring acetylation at lysine 36 (H3K36ac) instead (Figure 2B) . Additionally, peptide competition assays verified the interaction between the H3K14 antibodies and the H3K36ac peptide ( Figure 2C ). This result is likely explained by the fact that H3K14 and H3K36 are found in very similar sequence contexts and are acetylated by the same enzyme in vivo (Figure 2D) . Acetylation of both H3K14 and H3K36 is catalyzed by the histone acetyltransferase Gcn5 [13] . However, H3K14ac is reported to be recognized by the RSC complex in yeast, whereas H3K36ac has been reported to be recognized by the bromodomain of PCAF in human cells [14, 15] . Thus, misdetection of H3K36ac using H3K14ac-directed antibodies by either western blot or chromatin immunoprecipitation may obscure our understanding of chromatin-templated processes regulated by H3K14 acetylation.
The large number of synthetic peptides containing combinatorial PTMs allowed us to additionally ascertain how PTM recognition is influenced by neighboring modifications. We therefore did further analysis of the H3K4me3 antibodies to determine how adjacent modifications affect substrate recognition. We observed that a monoclonal antibody widely used against H3K4me3 (Abcam; catalog number ab1012) is perturbed mainly by modification at histone H3 arginine 2 (H3R2) ( Figure 3A ). In contrast, a widely used polyclonal antibody from Millipore (catalog number 07-473) was negatively influenced by H3T6 phosphorylation, and a similar antibody from Active Motif (catalog number 39160) was not particularly sensitive to any neighboring modifications ( Figure 3A ).
We also examined the well-characterized PTM ''switch'' region on histone H3, where H3K9 is modified by either acetylation or methylation and where the neighboring serine 10 (H3S10) is a target for phosphorylation [16] . A polyclonal antibody (Active Motif; catalog number 39253) raised against H3S10 phosphorylation showed a statistically significant reduction in binding to peptides also modified at H3K9 ( Figures 3B and 3C ). In contrast, an antibody raised against both H3S10phos and H3K9ac (Cell Signaling; catalog number 9711) showed nearly absolute specificity for the peptide containing both modifications ( Figures 3B and 3C ). These data can be interpreted to suggest that biological changes in acetylation and methylation at H3K9 would influence the ability of antibodies derived against H3S10 phosphorylation to appropriately detect this mark. Such findings are significant, because H3S10 phosphorylation levels have already been found to change during the cell cycle and in response to histone deacetylase inhibitors [17] [18] [19] .
Collectively, our analysis of histone PTM-specific antibodies enabled us to uncover recognition of related (but off-target) sequences in addition to adjacent PTM effects. This finding is significant because several major ongoing initiatives aimed at mapping and understanding how histone PTMs regulate biology, such as the National Institutes of Health (NIH) Epigenomic Roadmap and ENCODE, heavily rely on modification-specific antibodies [20] .
In addition to being a powerful diagnostic tool for the characterization of PTM-derived antibodies, we used our peptide array technology to measure how PTM codes affect the interaction of chromatin-associated proteins. Accordingly, we measured the binding of several domains known to interact with H3K4me3. We found that the PHD domain from the V(D)J recombination factor RAG2 was specific for H3K4me3 and was blocked by phosphorylation at either H3T3 or H3T6 ( Figure 4A ). From the structure of the RAG2 PHD domain bound to H3K4me3 peptide [21] , it can clearly be seen how H3T3 phosphorylation may disrupt binding. Varier and coworkers very recently published that H3T3 phosphorylation acts as a switch to control the binding of TAF3 PHD domain [22] . Thus, this may be a general mechanism for controlling gene expression during mitosis (when H3T3 is phosphorylated). Similarly, Garske and coworkers found that H3T6 phosphorylation may disrupt RAG2 binding [23] . We next examined the tandem bromo-PHD domains of BPTF (subunit of the NURF ATP-dependent remodeling complex [24] ). Our studies showed that the tandem domain was specific for H3K4me3 and also showed reduced binding in the presence of either H3T3 or H3T6 phosphorylation (Figure 4B) . However, both RAG2 and BPTF are blocked by citrulline, but not by methylation at position 2, suggesting a role for the positive charge of H3R2 in PHD domain binding. Notably, converting H3R2 to citrulline results in a loss of cationic charge and likely loss of ionic and hydrogen bonding interactions within the pockets of the two PHD domains (Figures 4A and  4B) . Interestingly, our ability to synthesize and print long peptides (R20 amino acids) allowed us to observe greater interactions of BPTF (PHD-bromo) with H3K4me3 peptides also harboring acetylation. We found that multiple acteylations on H3 enhanced the binding of BPTF to H3K4me3 ( Figure 4B and Figure S3 ), suggesting coordination between the methylbinding PHD domain and the acetyl-binding bromodomain to recognize multiple modifications on the histone H3 tail.
The chromodomain of human CHD1 is also known to recognize H3K4me3 but has a structurally distinct binding pocket from the PHD domains. We found that CHD1, like RAG2 and BPTF, preferentially binds H3K4me3 and is also negatively influenced by phosphorylation at H3T3 and H3T6 ( Figure 4C) . Interestingly, we also found that methylation of H3R2 appears to slightly enhance binding of CHD1, whereas citrullination at position 2 blocks this binding. Although the finding that H3R2 methylation reduces binding affinity of human CHD1 to H3K4me3 is in opposition to a previous report [25] , this discrepancy may be due to the fact that Flanagan and coworkers used peptides labeled at the N terminus with fluorescein in their binding studies, which may have contributed to the binding. Consistent with our CHD1 findings, we and others have found that H3R2 methylation does not decrease CHD1 binding to H3K4me3 by either isothermal titration calorimetry (data not shown) or fluorescence polarization using C-terminally labeled peptides (Marcey Waters, personal communication). H3R2 methylation and H3K4me3 have been found to be mutually exclusive in yeast and humans [26, 27] . Thus, H3R2 methylation and H3K4me3 may function in specific circumstances to prevent the binding of effector proteins that promote gene transcription while facilitating the recruitment of CHD1 (and possibly other factors) to genes in order to promote gene silencing.
In conclusion, the complex patterns of histone PTMs are critical determinants of chromatin structure and function, but they also represent a significant challenge for future study. Although many protein domains that bind selectively to particular PTMs have been identified, little is known regarding how neighboring modifications inhibit or contribute to these interactions. Of equal importance is our understanding of how patterns of PTMs influence antibody recognition. In this case, detection of biologically important events could be blocked or misrepresented if neighboring modifications interfere with epitope recognition. Thus, our work underscores a need for more rigorous testing and characterization of histone-specific antibodies. Similar antibody concerns have been recently highlighted by other groups [20, 28] . The data sets for the antibodies and proteins described here, plus numerous additional antibodies, are available in Figure S1 and from our website (http://www.med.unc.edu/wbstrahl/ Arrays/index.htm). In addition, we will continue to characterize histone antibody specificities and post the data to our website as an ongoing resource for the chromatin community.
Finally, although several other peptide array approaches have been used to measure binding to histone PTMs [8, [29] [30] [31] , our arrays and assay approaches offer several advantages. First, our array displays a large number of peptides carrying multiple PTMs that are fully characterized by highperformance liquid chromatography (HPLC) and mass spectrometry (MS). Second, we take advantage of a biotin tracer molecule to provide an assessment of printing efficiency. Table S1 , and further information is given in Figures S1 and S3 ). Lastly, the high density of spotting allows us to perform statistical analysis of binding interactions. Although Liu et al. recently reported a similarly semiquantitative approach, their arrays were largely limited to peptides containing single PTMs, and the peptides were labeled via their N terminus, which could potentially occlude proteins and antibodies from recognizing modifications such as H3K4 methylation [30] . Furthermore, cellulose SPOT synthesis technology is limited by the inability to analytically characterize peptides [28] . In addition, a very elegant bead-based approach has been used to generate even larger peptide libraries and successfully characterize the binding of several protein factors to combinatorial histone PTMs [23] . However, our approach offers advantages in that we obtain binding data for each individual peptide and do not require sophisticated MS for the analysis. Regardless, several technologies now exist to enable the development of PTM-specific antibodies with better specificity. Furthermore, these technologies are useful for understanding how combinations of PTMs coordinate protein-protein interactions. This has important implications not only for chromatin biologists but also for those who study the role of PTMs in other systems [32] .
Experimental Procedures Antibodies
All primary antibodies tested are commercially available and are listed in Table S2 . Secondary antibodies were Alexa Fluor 647 conjugated goat anti-rabbit IgG (catalog number A21244) and Alexa Fluor 647 conjugated rabbit anti-mouse IgG (catalog number A21239) antibodies from Invitrogen.
Peptide Synthesis
All reagents were obtained from commercial suppliers (AnaSpec, EMD, and Apptec). The peptides, biotinylated at their C termini, were synthesized on either NovaPEG Rink amide resin (histone H3 peptides) or Biotin-PEG NovaTag resin (histone H2A, H2B, and H4 peptides) using fluorenylmethyloxycarbonyl (Fmoc) chemistry on a PS-3 automated peptide synthesizer (see Table S1 for the complete list of peptides). All standard amino acids were coupled using HATU and N-methylmorpholine in dimethylformamide (DMF). Fmoc deprotection was performed using 20% piperidine in DMF. Modified amino acid residues were coupled using HATU, HOAt, and N,N,-diisopropyletylamine in NMP, and the coupling of these residues was monitored using ninhydrin test and repeated when needed. Peptides were cleaved from the resins using a 2.5% TIS and 2.5% water in trifluoroacetic acid (TFA). After TFA evaporation and washing with diethyl ether, the peptides were lyophilized from an acetonitrile/water solution and purified via preparative HPLC using water-acetonitrile gradient (0.1% TFA in both solvents) on a Waters SymmetryShield RP-18 5 mm 19 3 150 mm column. All peptides were analyzed using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and analytical HPLC. The average purity of peptides was over 90% (analytical HPLC). Analytical data for all peptides mentioned in this paper is available on our website.
Array Fabrication
Biotinylated peptides (25 mM final concentration) in printing buffer (10 mg/ml bovine serum albumin [BSA, Amresco], 0.3% Tween-20, and 10 mM biotinconjugated fluorescein added to 13 ArrayIt protein printing buffer) were arrayed onto SuperStreptavidin-coated slides (ArrayIt) using SMP6 stealth pins (w200 mm spot diameter) and were arrayed onto OmniGrid100 arrayer (Digilab/Genomic Solutions) at ambient temperature and humidity (50%-60%) using the following printing parameters. To minimize effects from individual pins or localized imperfections in the substrate arrays, we arrayed samples as a series of six spots, two times on each slide at a spacing of 375 mm, as indicated in Table S4 , and each peptide was printed by two different pins on each slide. After printing, slides were incubated overnight at 4 C in a humidified environment to facilitate interaction between the biotinylated peptide and the streptavidin surface. Slides were then blocked for 1 hr at 4 C with biotin-blocking buffer (ArrayIt), washed three times with phosphate-buffered saline (PBS), dried with air, stored at 4 C, and used within 60 days. Figure S3 .
Antibody Binding
Antibody dilutions were made in PBS containing 1% BSA (w10 mg/ml) and 0.3% Tween-20; the exact concentration for each array is summarized in Table S3 . Antibodies were incubated with printed slides for 90-180 min at 4 C (with the exception of the H3K4me3 monoclonal antibody from Abcam, which was incubated overnight) and washed three times with cold PBS. Arrays were then probed with the appropriate Alexa Fluor 647 conjugated secondary antibody (Invitrogen) for 30-60 min at 4 C, washed three times with cold PBS, and dried. Arrays were then scanned using a Typhoon TRIO+ imager (GE Healthcare) at 10 mm resolution using the 526 nm and 670 nm filter sets for the biotin-fluorescein and secondary antibody, respectively. Interactions were quantified using ImageQuant array software (GE Healthcare).
Protein Expression
The chromatin-associating domains from mouse RAG2 (PHD 387-493), human BPTF (Bromo and PHD domain 2583-2751), and CHD1 (chromodomain 251-467) were C-terminally fused to GST in pGEX-4T. Proteins were heterologously expressed in E. coli and purified by glutathione sepharose affinity chromatography in PBS buffer (50 mM phosphate, 150 mM NaCl, pH 7.6) on an AKTA purifier fast protein liquid chromatography system (GE Healthcare).
Protein Binding
Prior to binding, arrays were blocked in PBS containing 5% BSA (w50 mg/mL) and 0.3% Tween-20 for 1 hr at 4 C to reduce nonspecific binding. Glutathione S-transferase (GST)-tagged protein (w25 mM) in the same buffer was overlaid on each array (200 ml total volume) and incubated in a hybridization chamber at 4 C overnight. Slides were washed three times with cold PBS. Anti-GST primary antibody was incubated with slides for 90-180 min at 4 C and washed three times with cold PBS. Arrays were then probed with the Alexa Fluor 647 conjugated anti-rabbit secondary antibody (Invitrogen) for 30-60 min at 4 C, washed three times with cold PBS, and dried. Arrays were then scanned using a Typhoon TRIO+ imager (GE Healthcare) at 10 mm resolution using the 526 nm and 670 nm filter sets for the biotin-fluorescein and secondary antibody, respectively. Interactions were quantified using ImageQuant array software (GE Healthcare).
Statistical Analysis
Briefly, printing of individual spots was evaluated based on the intensity of the fluorescein-biotin cospotted with each peptide. Spots with control intensities of less than 5% of the average intensity for all peptides were labeled as ''not spotted'' and omitted from subsequent analysis. Data were treated as four individual subarrays to account for small changes in intensity across the slide, each subarray containing all 110 peptides spotted six times. Alexa Fluor 647 intensities (corresponding to a positive interaction) were normalized for all spots by dividing the intensity by the sum of all intensities within a subarray. The six spots for each peptide were averaged (outliers were removed using a Grubbs test) and treated as a single value for a given subarray. The normalized intensities for the four subarrays were used to calculate the mean, and the error is reported as the standard error of the mean. For data displayed as heat maps, mean values were normalized to either the highest calculated value across all peptides or against the peptide for which a given antibody was supposed to interact. Heat maps were created using Java Treeview, and all data were plotted on a scale from 0 to 1 ( Figure S1 ). Full data sets for all experiments are available at http://www.med.unc.edu/wbstrahl/Arrays/index.htm. Statistical analyses were performed using GraphPad Prism software. Analyses of variance were used to compare interactions, and confidence intervals are reported as 95% (*), 99% (**), or 99.9% (***). All models were constructed using PyMol software. Additional information is available in Figures S3 and S4 .
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